Hypertension as a predictive factor of Sunitinib activity

Open Access
Publisher Website
Google Scholar
Abstract
Sunitinib malate is a new reference standard for the treatment of metastatic renal cell carcinoma (mRCC) [1, 2]. Clinical or biological markers of activity and toxicity are warranted due to large variations in treatment response, as well as side effects. Hypertension is a major toxicity observed after most antiangiogenic treatments and is a potential signal of drug exposure. We aimed to retrospectively analyze a putative correlation between sunitinib activity and hypertension.